TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer

World Journal of Urology

Volumn 33, Issue 7, 2015, Pages 945-953

  Azzouzi, A R ^a   Barret, E ^b   Bennet, J ^c   Moore, C ^d   Taneja, S ^e   Muir, G ^f   Villers, A ^g   Coleman, J ^h   Allen, C ^d   Scherz, A ⁱ   Emberton, M ^d  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c Midtown Urology   (United States)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Focal therapy; Localized prostate cancer; Vascular targeted photodynamic therapy; WST11 TOOKAD Soluble

Indexed keywords

BACTERIOCHLOROPHYLL; PALLADIUM-BACTERIOPHEOPHORBIDE; PHOTOSENSITIZING AGENT;

HUMAN; MALE; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOCHEMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

BACTERIOCHLOROPHYLLS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84933177995     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1505-8     Document Type: Article

References (22)

1. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19
3. Parker WR, Montgomery JS, Wood DP Jr (2009) Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? Curr Opin Urol 19:303–308
4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213
5. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) Eau guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
6. Klotz L (2010) Active surveillance for prostate cancer: a review. Curr Urol Rep 11:165–171
7. Nomura T, Mimata H (2012) Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol 2012:391437
8. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Savard J, Wilson BC, Elhilali M (2007) Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178:1974–1979 discussion 1979
9. Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, Evans A, Scherz A, Savard J, Chin JL, Wilson BC, Elhilali M (2008) Vascular-targeted photodynamic therapy (padoporfin, wst09) for recurrent prostate cancer after failure of external beam radiotherapy: A study of escalating light doses. BJU Int 102:556–562
10. Mazor O, Brandis A, Plaks V, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A (2005) Wst11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 81:342–351
11. Madar-Balakirski N, Tempel-Brami C, Kalchenko V, Brenner O, Varon D, Scherz A, Salomon Y (2010) Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (vtp) with tookad. PLoS One 5:e10282
12. Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y (2003) Photodynamic therapy with pd-bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 104:782–789
13. Fleshker S, Preise D, Kalchenko V, Scherz A, Salomon Y (2008) Prompt assessment of wst11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate. Photochem Photobiol 84:1231–1237
14. Brandis A, Mazor O, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A (2005) Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol 81:983–993
15. Ashur I, Goldschmidt R, Pinkas I, Salomon Y, Szewczyk G, Sarna T, Scherz A (2009) Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative wst11, noncovalently bound to serum albumin. J Phys Chem A 113:8027–8037
16. Betrouni N, Lopes R, Puech P, Colin P, Mordon S (2011) A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble wst11. Phys Med Biol 56:4771–4783
17. Moore CM, Azzouzi AR, Barret E, Villers A, Muir G, Barber N et al (2014) Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localized prostate cancer using WST11-Vascular Targeted Photodynamic (VTP) therapy. BJU Int. doi:10.1111/bju.12816
18. Azzouzi AR, Barret E, Moore CM, Villers A, Allen C, Scherz A, Muir G, de Wildt M, Barber NJ, Lebdai S, Emberton M (2013) TOOKAD((r)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112:766–774
19. Moore CM, Pendse D, Emberton M (2009) Photodynamic therapy for prostate cancer—a review of current status and future promise. Nat Clin Pract Urol 6:18–30
20. Lepor H (2008) Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol 10:254–261
21. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445
22. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD (2008) Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 180:1964–1967 discussion 1967–1968